Sympathetic nervous response to ischemia-reperfusion injury in humans is altered with remote ischemic preconditioning

Elisabeth A. Lambert,1,5 Colleen J. Thomas,2 Robyn Hemmes,1 Nina Eikelis,1 Atul Pathak,3 Markus P. Schlaich,* and Gavin W. Lambert1,6

1Human Neurotransmitters Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; 2Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, Melbourne, Victoria, Australia; 3Centre de Recherche Clinique Cardiovasculaire Pasteur, Centre Hospitalier Universitaire, Toulouse, France; 4School of Medicine and Pharmacology, Royal Perth Hospital Unit, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, Western Australia, Australia; 5Department of Physiology, Monash University, Clayton, Victoria, Australia; and 6Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia

Submitted 13 May 2016; accepted in final form 7 June 2016

Lambert EA, Thomas CJ, Hemmes R, Eikelis N, Pathak A, Schlaich MP, Lambert GW. Sympathetic nervous response to ischemia-reperfusion injury in humans is altered with remote ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 311: H364–H370, 2016. First published June 10, 2016; doi:10.1152/ajpheart.00369.2016.—Sympathetic neural activation may be detrimentally involved in tissue injury caused by ischemia-reperfusion (IR). We examined the effects of experimental IR in the forearm on sympathetic nerve response, finger reactive hyperemia, and oxidative stress, and the protection afforded by applying remote ischemic preconditioning (RIPC). Ischemia was induced in the forearm for 20 min in healthy volunteers. RIPC was induced by applying two cycles, 5 min each, of ischemia and reperfusion to the upper leg immediately before IR. We examined muscle sympathetic nerve activity (MSNA) in the contralateral leg, erythrocyte reactive hyperemia, oxidative stress, and the reduction of NO availability, decreased during the reperfusion period in control group (p < 0.05), but not in those who underwent RIPC. Nitrate and nitrite concentration, taken as an index of NO availability, increased during ischemia and increased only by 40%. GSH increased during ischemia and increased only by 40%. GSH increased during ischemia in the control group (p < 0.05). In subjects who underwent RIPC (n = 15), the increase in MSNA was delayed to the late phase of ischemia and increased only by 40%. GSH increased during ischemia in the control group (p = 0.05), but not in those who underwent RIPC. Nitrate and nitrite concentration, taken as an index of NO availability, increased during the reperfusion period in control individuals (p < 0.05), while no change was observed in those who underwent RIPC. Experimental IR did not affect RHI in the control condition, but a significant vasodilatory response occurred in the RIPC group (P < 0.05). RIPC attenuated ischemia-induced sympathoexcitation, prevented the production of an erythrocyte marker of oxidative stress and the reduction of NO availability, and ameliorated RHI.

ischemia-reperfusion injury; remote conditioning; endothelial function; oxidative stress; sympathetic nervous system

NEW & NOTEWORTHY

Muscle sympathetic nervous system (SNS) increases during forearm ischemia-reperfusion (IR) in healthy individuals. When remote ischemic preconditioning (RIPC) was applied before IR, the SNS response was delayed and attenuated, indicating that modulation of the SNS may play a role in the beneficial effects afforded by RIPC.

LOCAL ISCHEMIC PRECONDITIONING is an established method to protect the heart against tissue damage induced by prolonged ischemia and subsequent reperfusion (9). Although recently disputed in large-scale studies (5, 24), data from smaller size clinical trials indicate that brief periods of ischemia applied at an easily accessible remote site, usually a limb, before an injurious ischemic event [remote ischemic preconditioning (RIPC)] ameliorates myocardial injury following coronary artery bypass graft surgery (6) and lowers all-cause mortality (30). Experimental studies indicate that the protection afforded by RIPC can also impact other organs, such as the kidneys, brain, and liver (10). The pathway generating distant organ protection remains unclear, but is believed to involve both humoral and neural mechanisms. Humoral mediators, such as adenosine, bradykinin, and opioids, have been proposed as necessary triggers for preconditioning the heart. RIPC may also act by improving endothelial dysfunction and reducing inflammation and reactive oxygen species (ROS) formation (20). Indeed, studies in humans have shown that RIPC can either improve endothelial function (22), or prevent ischemia-reperfusion (IR)-induced endothelial dysfunction as well as prevent systemic neutrophil activation (15). Sympathetic nervous activation and norepinephrine overflow is a key component of the IR-induced organ injury (11), and pharmacological sympathoinhibition was found to prevent the ischemic kidney injury in rats (32), thereby indicating the potential deleterious effect of ischemia-induced sympathetic activation. In addition, it was found that ischemic preconditioning suppressed the enhanced renal sympathetic nerve activity during ischemia, probably through activation of nitric oxide (NO) production (33). However, the effects of IR and preconditioning on sympathetic nervous system activation have not been fully explored in humans. We evaluated sympathetic nerve response by direct microneurographic recordings, finger reactive hyperemia, noradrenaline, NO, and ROS release to forearm IR injury in healthy humans and determined whether RIPC performed in the leg altered these responses.

METHODS

Thirty healthy volunteers (13 men, 17 women; mean age, 21 yr, range, 18–39 yr) were recruited. The study protocol conformed to relevant guidelines of the National Health and Medical Research Council of Australia and was approved by The Alfred Hospital Human Research Ethics Committee. All participants gave written, informed consent before their participation.
IR and RIPC. Participants were studied in the supine position. The IR injury was performed in the left upper arm (occluding the brachial artery). Ischemia was induced by inflating a 9-cm-wide blood pressure (BP) cuff to a pressure of 200 mmHg for 20 min. Reperfusion was induced by deflating the cuff. The RIPC was performed in the upper part of the left leg using a 9-cm-wide BP cuff. The cuff was inflated to 200 mmHg for 5 min (ischemia), followed by a 5-min deflation (reperfusion). The inflation/deflation cycle was performed two times. RIPC was initiated immediately before the IR injury induction. Participants were randomly assigned to be in a control group (no RIPC, \( n = 15 \)) or RIPC (\( n = 15 \)).

Experimental protocol. The experimental protocol is illustrated in Fig. 1. First, a venous catheter was placed in an antecubital vein of the right arm. Microneurographic recording of muscle sympathetic nerve activity (MSNA) was then commenced. After a robust MSNA site was found, participants were allowed to rest for 20 min to obtain baseline measurements. Endothelial function measurements commenced after the baseline period. RIPC or no intervention (control group) was conducted for a total period of 20 min and was followed by a 20-min period of ischemia and another 20-min period of reperfusion. Endothelial function assessment was repeated immediately after the IR injury. Blood samples were collected from participants within the last 2 min of the following periods: 1) baseline, 2) forearm ischemia; and 3) forearm reperfusion.

MSNA and hemodynamic recordings. Recording of multunit postganglionic MSNA in humans was performed as previously described (17). Briefly, recordings were made from a tungsten microelectrode (FHC, Bowdoinham, ME) inserted directly into the right peroneal nerve just below the fibular head. During MSNA recording, beat-to-beat BP was measured continuously using the Finometer system (Finapress Medical System BV, Amsterdam, The Netherlands). Brachial BP was assessed every 15 min (Dinamap model 1846SX, Critikon, Tampa, FL) to ensure correct readings. Heart rate (HR) was extracted from lead III ECG. All of these parameters were digitized with a sampling frequency of 1,000 Hz (PowerLab recording system, model ML 785/8SP, ADI Instruments). Sympathetic bursts were counted manually and expressed as burst incidence (bursts/100 heart-beats) and burst frequency (bursts/min). Average MSNA, BP, and HR were performed over a period of \( \approx 5 \) min at the end of baseline, just before IR (end of RIPC period), in the early (4–8 min) and late (16–20 min) phase of ischemia, and in the early and late phase of reperfusion.

Finger reactive hyperemia. Fingertip pulse-volume amplitude was measured to calculate reactive hyperemia index (RHI), assessed as the ratio of peripheral microvascular endothelial function. Finger reactive hyperemia was evaluated noninvasively in the index finger of the left hand of participants using the EndoPAT 2000 device (Itamar Medical, Caesarea, Israel). A beat-to-beat plethysmographic recording of the arterial pulse wave was obtained over 5 min of rest. Brachial arterial occlusion was then induced by inflating an upper arm cuff to suppress systolic pressure (60 mmHg above systolic pressure) for 5 min and released to elicit reactive flow-mediated hyperemia. Pulse amplitude responses to hyperemia were calculated from the hyperemic fingertip as the ratio of the postdeflation pulse amplitude to amplitude responses to hyperemia were calculated from the hyperemic fingertip as the ratio of the postdeflation pulse amplitude to amplitude responses to hyperemia. Pulse amplitude responses to hyperemia were calculated from the hyperemic fingertip as the ratio of the postdeflation pulse amplitude to amplitude responses to hyperemia. Finger reactive hyperemia index (RHI) indicated that finger hyperemia index correlated with values of flow-mediated dilatation (FMD) by means of brachial artery ultrasound scanning (16).

Blood samples. Venous blood (2 \( \times \) 10 ml) was collected into chilled tubes containing ethylenediaminetetraacetic acid. One tube of blood was immediately used to measure glutathione levels in fresh blood. The remainder of the blood was centrifuged (3,500 rpm for 15 min at 4°C), and the plasma was stored in a \( -80^\circ \)C freezer until later measurement of total nitrate (\( \text{NO}_3^- \))/nitrite (\( \text{NO}_2^- \)) concentration and noradrenaline concentration.

Assessment of NO release. From plasma, we measured \( \text{NO}_3^- \) and \( \text{NO}_2^- \) as an indicator of total NO production (31). We used the commercial colorimetric kit from Cayman Chemical (Ann Arbor, MI) and followed the manufacturer’s instructions. The final products of NO in vivo are \( \text{NO}_3^- \) and \( \text{NO}_2^- \), with the best index of NO production being the sum of both \( \text{NO}_3^- \) and \( \text{NO}_2^- \). Measurement of total \( \text{NO}_3^- / \text{NO}_2^- \) concentration was achieved in a two-step process. The first step involved the conversion of \( \text{NO}_3^- \) to \( \text{NO}_2^- \) using nitrite reductase. In the second step, addition of the Griess reagent resulted in the conversion of \( \text{NO}_2^- \) into a deep purple compound, which was photometrically measured using a Benchmark Plus Microplate spectrophotometer (Bio-Rad Laboratories, Hercules, CA). The Griess reaction is the most frequently used analytic method for quantification of the major metabolites of NO (\( \text{NO}_3^- \) and \( \text{NO}_2^- \)) in blood (31).

Assessment of erythrocyte markers of oxidant stress. Erythrocyte production of reduced glutathione (GSH) was determined by the method of Beutler et al. (1). This method is based on the principle that GSH reduction of 5,5-dithiobis (2-nitrobenzoic acid) forms a yellow colored anion, which can be measured spectrophotometrically at 412 nm. A GSH standard was prepared by adding 50 mg GSH and deionized water to a final volume of 100 ml. Two hundred microliters of the washed cell suspension or standard, 1.8 ml deionized water, and 3 ml of precipitating solution (8.35 g glacial metaphosphoric acid, 1 g di-potassium EDTA, 150 g sodium chloride in 500 ml deionized water) were added to a test tube. The mixture was then left to stand for 5 min to allow proteins to precipitate. Proteins were then filtered using a glass funnel, and 1 ml of the sample filtrate or GSH standard was added to 10 ml phosphate solution containing 0.3 M di-sodium hydrogen phosphate. Five hundred microliters of 5,5-dithiobis-2-nitrobenzoic acid solution (0.5 mM in 1% tri-sodium citrate) was then added, and the absorbance was measured at 412 nm. The GSH concentration of the samples (mg GSH/100 ml erythrocytes) was determined using the absorbance value of the GSH standard, and the hematocrit was determined on the washed cell suspension.

Plasma noradrenaline concentration. Noradrenaline was extracted from plasma using alumina absorption, and the amount was quantified using high-performance liquid chromatography with colorimetric detection, as previously described by our laboratory (18). Intra-assay coefficient of variation in our laboratory is 1.3%, and interassay coefficient of variation is 3.8%.

Statistics. All data are expressed as means \( \pm \) SE. MSNA, BP, HR, RHI, plasma noradrenaline concentrations, and GSH were evaluated using two-way repeated-measures analysis of variance, testing for protocol effects (control vs. RIPC), RIPC and IR effects, and interactions. As NO data were not normally distributed, a Friedman repeated-measures ANOVA on ranks was used. GSH changes be-

Fig. 1. Protocol. Protocol to determine the effects of forearm ischemia-reperfusion injury and the impact of remote ischemic preconditioning (RIPC) vs. control (CON) on muscle sympathetic nerve activity (MSNA) and finger reactive hyperemia index (RHI). Blood samples, indicated by triangles, were taken 5 min before the end of the baseline, ischemia, and reperfusion periods.

AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00369.2016 • www.ajpheart.org

SYMPATHETIC ACTIVITY AND ISCHEMIC PRECONDITIONING

H365
between the two groups observed during ischemia were assessed as percent change and analyzed using an independent Student’s *t*-test. Differences were considered significant at *P* < 0.05. Statistical analysis was performed using SigmaStat for Windows version 3.5.

**RESULTS**

All participants tolerated the procedure without complication. BP did not change during the procedure, as shown in Fig. 2. Mean resting systolic and diastolic BP was 111 ± 3 and 67 ± 1 mmHg and 112 ± 4 and 65 ± 3 mmHg for the control and RIPC group, respectively. Average baseline HR was 64 ± 3 and 61 ± 3 beats/min, for the control and RIPC group, respectively. HR remained unchanged during the entire protocol in the two groups, with the HR being 66 ± 4 and 62 ± 3 beats/min at the end of the study in the control and RIPC group, respectively.

**Sympathetic nerve response.** Microneurographic recordings were maintained for the duration of the study in 18 subjects (8 controls and 10 RIPC); hence MSNA data are presented in this cohort only. An example of MSNA response in one control subject and one RIPC subject is presented in Fig. 3. In the control group, MSNA was 20 ± 2 and 22 ± 2 bursts/min at baseline and just before IR injury, respectively. Ischemia was associated with an increase in MSNA to 31 ± 2 bursts/min in the early phase (*P* = 0.033 vs. baseline) and to 35 ± 2 bursts/min in the late phase (*P* < 0.001 vs. baseline). During reperfusion, MSNA was no longer different from the baseline values (28 ± 2 and 21 ± 2 bursts/min in the early and late phase of reperfusion, respectively). In the group that underwent RIPC, MSNA was 21 ± 2 bursts/min at baseline. The RIPC did not significantly affect MSNA (16 ± 2 bursts/min). In the early phase of ischemia, MSNA remained unchanged (22 ± 2 bursts/min), but significantly increased during the late phase (29 ± 2 bursts/min, *P* < 0.001 compared with RIPC values). The increase in MSNA during the early phase of ischemia was significantly less in the RIPC group compared with the control one [change (Δ) = 8.3 bursts/min, *P* = 0.028, RIPC vs. control group].

When expressed as percent change from baseline, the increase in MSNA (bursts/min) was 70 and 101% during the early and late phase of the ischemia, respectively, and 55% during the early phase of reperfusion in the control group. These changes were significantly different from the changes observed before IR (*P* = 0.018, *P* < 0.01, and *P* = 0.15, respectively). In the RIPC group, MSNA changes during RIPC

![Fig. 2. Blood pressure (BP). Systolic and diastolic BP obtained in control subjects and in subjects submitted to remote ischemic preconditioning (RIPC) at baseline and during the RIPC, early and late phase of ischemia (Isch), and early and late phase of reperfusion (Rep). Values are means ± SE.](image-url)

![Fig. 3. Recordings of sympathetic nerve activity. Examples of muscle sympathetic nerve activity (MSNA) traces obtained in a control subject (A) and a subject submitted to remote ischemic preconditioning (B) at baseline and during ischemic and reperfusion periods. The top traces show continuous MSNA recordings, and the bottom graphs show the traces over a selected 1-min period at baseline and in the early and late phase of both ischemia and reperfusion.](image-url)
were not significantly altered compared with baseline (−24%),
but the increase in MSNA during the late phase of ischemia
was significantly different compared with the changes ob-
served during RIPC (40%, \( P = 0.011 \)). Nevertheless, the
changes in MSNA during both the early and late phases of
ischemia were less than those seen in the control group (\( P <
0.05 \) compared with controls at both early- and late-phase time
points) (Fig. 4). MSNA expressed as burst incidence (bursts/
100 heartbeats) displayed similar changes as that expressed as
burst frequency (data not shown).

**Finger reactive hyperemia.** Finger reactive hyperemia mea-
surements were successfully obtained both before and after the
procedure in 11 subjects in each group. In the control group,
the IR injury did not significantly affect finger reactive hyper-
emia (RHI: 1.68 ± 0.2 vs. 1.86 ± 0.12 at baseline), whereas,
in subjects who underwent RIPC, finger reactive hyperemia
was significantly improved compared with baseline (2.28 ±
0.2 vs. 1.81 ± 0.08, \( P = 0.002 \)) (Fig. 5). After IR injury, RHI
was also significantly higher in the RIPC group compared with
the control group (\( P = 0.028 \), Fig. 5).

**Erythrocyte marker of oxidant stress.** In the control group,
erthrocyte production of GSH increased during ischemia
(77.6 ± 1.1 vs. 73.4 ± 1 mg/100 ml red blood cells, \( P = 0.05 \)),
and this increase was absent in those subjected to RIPC
(75.1 ± 2.3 vs. 77.8 ± 1.2 mg/100 ml red blood cells; Fig. 6A).
Increases in GSH during ischemia reached 6% in the control
group, this increase was absent in those subjected to RIPC
\((40\%, \ P = 0.011)\). Nevertheless, the changes in GSH during
both the early and late phases of ischemia were less than those
seen in the control group (\( P < 0.05 \) compared with controls at both early-
and late-phase time points) (Fig. 6B).

**NO production.** In the control group, NO was not affected
during the end of the ischemic period, but significantly
decreased during reperfusion (79 ± 10 vs. 71 ± 8 \( \mu \)M, \( P =
0.018 \)). In subjects submitted to RIPC, no change in NO was
noted at either ischemic or reperfusion periods (62 ± 3 vs.
62 ± 2 \( \mu \)M) (Fig. 7).

**Plasma noradrenaline concentration.** In the control group,
plasma noradrenaline concentrations did not change during the
protocol (253 ± 17 pg/ml at baseline, 215 ± 17 pg/ml during
ischemia, and 216 ± 17 pg/ml during reperfusion). In the RIPC
group, there was a small decrease in plasma noradrenaline
centration during the reperfusion period (279 ± 16 pg/ml at
baseline, 223 ± 16 pg/ml during ischemia, and 209 ± 16 pg/ml
during reperfusion; \( P = 0.016 \) compared with baseline). Over-
all, the change in noradrenaline seen during the reperfusion
period in RIPC subjects (−21%) was not significantly different
from that of the controls (−2%, \( P = 0.241 \)).

**DISCUSSION**

To our knowledge, this is the first study to demonstrate that
forearm IR in humans is associated with sympathetic nervous
activation, and that RIPC attenuates and delays sympathetic
activation seen during the ischemic period. RIPC-induced
sympathetic attenuation during ischemia was associated with
improved RHI, a surrogate marker of endothelial function, and
prevention of an indirect marker of oxidant stress formation
and prevention of decreased of NO\(_3\) and NO\(_2\), an index of NO
availability. Our study highlights that the protection offered by
RIPC in healthy humans may involve the attenuation of the
sympathetic nervous system activity and associated endothelial
mechanisms.

During myocardial (11, 28) or renal (29) ischemia, a signif-
ificant amount of norepinephrine is released from sympathetic
nerve terminals, causing myocardial or renal hemodynamic
and histological damage. In a rat model, Tsutsui et al. (33)
documented that renal sympathetic nerve activity increased by
109% immediately after the start of renal ischemia, and that
this was accompanied by increased renal venous plasma nor-
epinephrine after reperfusion and severe lesions in the medulla,
medullary congestion, hemorrhage, and tubular necrosis. In
humans, brief (elective coronary angioplasty) or severe pro-
longed ischemia (acute myocardial infarction) are accompa-
nied by elevated plasma norepinephrine levels (27). Indeed,
norepinephrine release is thought to be critically involved in the progression of ischemic cell damage and the occurrence of ventricular fibrillation in early ischemia (28). In the present study, direct sympathetic nerve recording was performed at a site remote from the ischemic organ. Ischemia rapidly induced sustained sympathetic activation, in the order of 101% after 15 min. This sympathoexcitation subsided during the reperfusion phase. This profile of response was not associated with hemodynamic change, in line with that previously described (15). Moreover, plasma noradrenaline concentrations were unchanged. This suggests that the sympathoexcitation we observed may not be generalized, and/or other vascular beds may not be affected similarly. We must, however, point out that plasma noradrenaline has limited ability to reflect sympathetic drive compared with muscle sympathetic nerve traffic (4). Our model elicits a moderate ischemic injury as sympathetic responses were similar to that expected during a very short challenge combining muscle contraction and ischemia (23).

The RIPC performed in the upper part of the leg did not change MSNA significantly. Nevertheless, the sympathetic activation induced by IR was still present in the late phase of the ischemia, albeit to a lower level, indicating that RIPC was able to reduce the immediate muscle sympathetic activation induced by ischemia, but did not abolish it completely, particularly in the latter phase. Separately, we observed that, during the reperfusion period, plasma noradrenaline concentration slightly decreased in those who underwent RIPC, but the change was not statistically different from that of the control group. Interestingly, in a rat model of renal ischemia (33), it was found that ischemic preconditioning at the site of ischemia almost completely reduced renal sympathetic nerve activation during renal IR injury and attenuated the IR-induced renal dysfunction and histological damage. Taken together, this suggests that sympathoinhibitory effects may partly be involved in the protective mechanisms of ischemic preconditioning.

Changes in endothelial function have been reported in diverse tissues after IR (8). Reestablishment of blood flow induces blood to rapidly perfuse the vasculature, allowing the rapid reintroduction of molecular oxygen triggering the generation of oxygen-derived free radicals and decreased NO bioavailability (19). Given that endothelial cells are susceptible to IR injury, enhanced or preserved endothelial function may play a role in tissue protection during IR. We noted that RHI, an index of endothelial function, was significantly higher following IR in the subjects submitted to RIPC, suggesting improved local endothelial function. This finding is in line with a recent report showing improvement in the endothelial function of patients undergoing ischemic preconditioning before primary percutaneous coronary intervention (22). In the present study, the possibilities to explain the enhanced RHI induced by RIPC may include the protection of the availability of NO (26), the reduced formation of ROS, such as was recently demonstrated in a rat model of mesenteric ischemia (7), or the reduced

Fig. 6. Erythrocyte production of reduced glutathione (GSH). A: erythrocyte production of GSH in control subjects and subjects submitted to remote ischemic preconditioning (RIPC) at baseline, end of ischemia, and reperfusion periods. RBC, red blood cells. B: % change in GSH during ischemia. Values are means ± SE. *P = 0.05, time effect. #P < 0.01.

Fig. 7. Nitric oxide (NO) concentration. NO concentration is shown in plasma from control subjects and subjects submitted to remote ischemic preconditioning (RIPC) at baseline, end of ischemia, and reperfusion periods. Values are means ± SE. *P < 0.05, time effect.
activation of the sympathetic nervous system activity. In our model of ischemia, we observed a small but significant increase in production of GSH after 20 min of ischemia in the control subjects, while this rise was not observed in subjects submitted to RIPC. Erythrocyte production of GSH, an antioxidant released to defend against oxidative damage, would be expected to decrease during ischemia. Therefore, the response may reflect an increased production of ROS (12), perhaps as an adaptive response to oxidative challenge. Indeed, GSH has been shown to increase following acute myocardial infarction (12). Our data may indicate that RIPC prevents the production of ROS and hence the release of antioxidant defenses; however, we acknowledge that the changes were very small.

Whether the buffering of the sympathetic activation is due to better availability of NO induced by RIPC is uncertain because, in our IR model, sympathetic activation was transient, being only seen during the ischemic period, while the decrease in concentration of NO and NO$_2^-$ used as an index of NO availability seemed to occur only during the reperfusion period and was marginal. Experimental studies have also demonstrated that ROS may increase sympathetic nervous system activity through decreased production/availability of NO and interleukin-1 (2), suggesting that, during ischemia, these processes are most likely closely linked. Conversely, one could postulate that ischemia-induced increased sympathetic nervous system activity could also reduce NO availability and aggravate endothelial function, as a recent study indicated that the sympathetic nervous system regulates the mobilization and recruitment of endothelial progenitor cells in mice during hindlimb ischemia (13).

Limitations of the study include the assessment in young, healthy individuals who are unlikely to experience an ischemic event and the use of a mild level of ischemia compared with what patients may experience during an ischemic event. Hence, we cannot determine whether an older population at high cardiovascular risk may show comparable sympathetic buffering response to RIPC following an ischemic injury. This issue was raised in a previous study showing that older age is associated with an abolished effect of RIPC to protect against endothelial dysfunction after IR in the brachial artery (34). In addition, older age and increased cardiovascular risk are typically associated with altered sympathetic nervous function at rest and during physiological challenges (14). Sympathetic tone was measured in the skeletal muscle in the right leg, and, given that sympathetic tone is highly regionalized (3), this may not reflect the response in other vascular beds. An indirect index of endothelial function was measured, before inducing the sequences of RIPC and IR. This involved the induction of a 5-min ischemia in the forearm, which may, in itself, already induce a protective effect, although the protection mechanism is usually described as two or three cycles of IR (21). The Endopat device uses a reactive hyperemia peripheral arterial tonometry approach, which measures pulse volume changes at the fingertips after an occlusion of the brachial artery. The gold standard method to assess vascular endothelial function is FMD by means of brachial artery ultrasound scanning. The method we used was recently shown to have higher within-day variability compared with FMD (25); however, it has the advantage of being operator independent and shows a significant correlation with FMD (16).

Conclusion and perspective. This study indicates that, in a human model of IR, RIPC is able to reduce and delay the degree of sympathetic nervous activation and ameliorate RHI, an index of endothelial function in the ischemic tissue. Prevention of decreased NO bioavailability and increased generation of ROS may be among the mechanisms involved. This observation underlines that modulation of sympathetic activity may play a role in the protective effects of RIPC, at least in the short term. While observational data suggested that RIPC administered to patients undergoing cardiac surgery resulted in beneficial clinical outcomes (6, 30), two recent large-scale, prospective, randomized, sham-controlled trials of RIPC in patients undergoing cardiac surgery and requiring cardiopulmonary bypass were negative (5, 24). This raises the issue that RIPC may offer protection only in certain patient groups. It is possible that the protective effects of RIPC may be masked by factors, such as pharmacological agents, older age, or underlying pathology, that interfere with either neural or humoral mechanisms involved in RIPC processes. The pathways by which RIPC may offer protection and its possible limitations need to be further evaluated in a wider group of patients.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES

H370 SYMPATHETIC ACTIVITY AND ISCHEMIC PRECONDITIONING


